ZA200301740B - HIV peptides from conserved regions in gas P17 and P24 and their application in e.g. vaccines. - Google Patents

HIV peptides from conserved regions in gas P17 and P24 and their application in e.g. vaccines. Download PDF

Info

Publication number: ZA200301740B
Authority: ZA; South Africa
Prior art keywords: liquid; solvent; vapour; pressure vessel; vessel
Prior art date: 2000-09-04

Application number

ZA200301740A

Other languages

English (en)

Inventor

Birger Soeensen

Original Assignee

Bionor Immuno As

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-09-04

Filing date

2001-09-03

Publication date

2004-06-21

2001-09-03 Application filed by Bionor Immuno As filed Critical Bionor Immuno As

2004-06-21 Publication of ZA200301740B publication Critical patent/ZA200301740B/en

Links

102000004196 processed proteins & peptides Human genes 0.000 title 1
108090000765 processed proteins & peptides Proteins 0.000 title 1
229960005486 vaccine Drugs 0.000 title 1
239000002904 solvent Substances 0.000 claims description 59
239000007788 liquid Substances 0.000 claims description 42
239000002028 Biomass Substances 0.000 claims description 22
239000000284 extract Substances 0.000 claims description 22
238000000605 extraction Methods 0.000 claims description 19
238000000034 method Methods 0.000 claims description 17
239000007921 spray Substances 0.000 claims description 14
239000000203 mixture Substances 0.000 claims description 12
238000001704 evaporation Methods 0.000 claims description 9
230000008020 evaporation Effects 0.000 claims description 9
238000009834 vaporization Methods 0.000 claims description 8
238000010438 heat treatment Methods 0.000 claims description 7
230000001419 dependent effect Effects 0.000 claims 1
238000013022 venting Methods 0.000 claims 1
239000000047 product Substances 0.000 description 13
239000000463 material Substances 0.000 description 12
238000009835 boiling Methods 0.000 description 11
LVGUZGTVOIAKKC-UHFFFAOYSA-N 1,1,1,2-tetrafluoroethane Chemical compound FCC(F)(F)F LVGUZGTVOIAKKC-UHFFFAOYSA-N 0.000 description 6
230000008569 process Effects 0.000 description 6
239000012530 fluid Substances 0.000 description 5
RWRIWBAIICGTTQ-UHFFFAOYSA-N difluoromethane Chemical compound FCF RWRIWBAIICGTTQ-UHFFFAOYSA-N 0.000 description 4
NBVXSUQYWXRMNV-UHFFFAOYSA-N fluoromethane Chemical compound FC NBVXSUQYWXRMNV-UHFFFAOYSA-N 0.000 description 4
AWTOFSDLNREIFS-UHFFFAOYSA-N 1,1,2,2,3-pentafluoropropane Chemical compound FCC(F)(F)C(F)F AWTOFSDLNREIFS-UHFFFAOYSA-N 0.000 description 3
230000008859 change Effects 0.000 description 3
239000010408 film Substances 0.000 description 3
150000005828 hydrofluoroalkanes Chemical class 0.000 description 3
MSSNHSVIGIHOJA-UHFFFAOYSA-N pentafluoropropane Chemical compound FC(F)CC(F)(F)F MSSNHSVIGIHOJA-UHFFFAOYSA-N 0.000 description 3
238000011084 recovery Methods 0.000 description 3
230000009467 reduction Effects 0.000 description 3
238000000926 separation method Methods 0.000 description 3
FYIRUPZTYPILDH-UHFFFAOYSA-N 1,1,1,2,3,3-hexafluoropropane Chemical compound FC(F)C(F)C(F)(F)F FYIRUPZTYPILDH-UHFFFAOYSA-N 0.000 description 2
NSGXIBWMJZWTPY-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropane Chemical compound FC(F)(F)CC(F)(F)F NSGXIBWMJZWTPY-UHFFFAOYSA-N 0.000 description 2
UJPMYEOUBPIPHQ-UHFFFAOYSA-N 1,1,1-trifluoroethane Chemical compound CC(F)(F)F UJPMYEOUBPIPHQ-UHFFFAOYSA-N 0.000 description 2
WXGNWUVNYMJENI-UHFFFAOYSA-N 1,1,2,2-tetrafluoroethane Chemical compound FC(F)C(F)F WXGNWUVNYMJENI-UHFFFAOYSA-N 0.000 description 2
NPNPZTNLOVBDOC-UHFFFAOYSA-N 1,1-difluoroethane Chemical compound CC(F)F NPNPZTNLOVBDOC-UHFFFAOYSA-N 0.000 description 2
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
241000196324 Embryophyta Species 0.000 description 2
XPDWGBQVDMORPB-UHFFFAOYSA-N Fluoroform Chemical compound FC(F)F XPDWGBQVDMORPB-UHFFFAOYSA-N 0.000 description 2
239000013543 active substance Substances 0.000 description 2
239000000796 flavoring agent Substances 0.000 description 2
235000019634 flavors Nutrition 0.000 description 2
239000003205 fragrance Substances 0.000 description 2
GTLACDSXYULKMZ-UHFFFAOYSA-N pentafluoroethane Chemical compound FC(F)C(F)(F)F GTLACDSXYULKMZ-UHFFFAOYSA-N 0.000 description 2
238000003860 storage Methods 0.000 description 2
239000010409 thin film Substances 0.000 description 2
SUAMPXQALWYDBK-UHFFFAOYSA-N 1,1,1,2,2,3-hexafluoropropane Chemical compound FCC(F)(F)C(F)(F)F SUAMPXQALWYDBK-UHFFFAOYSA-N 0.000 description 1
ZDCWZRQSHBQRGN-UHFFFAOYSA-N 1,1,1,2,3-pentafluoropropane Chemical compound FCC(F)C(F)(F)F ZDCWZRQSHBQRGN-UHFFFAOYSA-N 0.000 description 1
WZLFPVPRZGTCKP-UHFFFAOYSA-N 1,1,1,3,3-pentafluorobutane Chemical compound CC(F)(F)CC(F)(F)F WZLFPVPRZGTCKP-UHFFFAOYSA-N 0.000 description 1
MWDWMQNTNBHJEI-UHFFFAOYSA-N 1,1,2,3,3-pentafluoropropane Chemical compound FC(F)C(F)C(F)F MWDWMQNTNBHJEI-UHFFFAOYSA-N 0.000 description 1
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
240000007154 Coffea arabica Species 0.000 description 1
244000018436 Coriandrum sativum Species 0.000 description 1
235000002787 Coriandrum sativum Nutrition 0.000 description 1
244000304337 Cuminum cyminum Species 0.000 description 1
235000007129 Cuminum cyminum Nutrition 0.000 description 1
240000006927 Foeniculum vulgare Species 0.000 description 1
235000004204 Foeniculum vulgare Nutrition 0.000 description 1
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
240000007232 Illicium verum Species 0.000 description 1
235000008227 Illicium verum Nutrition 0.000 description 1
-1 R-227ea Chemical compound 0.000 description 1
244000223014 Syzygium aromaticum Species 0.000 description 1
235000016639 Syzygium aromaticum Nutrition 0.000 description 1
240000006064 Urena lobata Species 0.000 description 1
244000273928 Zingiber officinale Species 0.000 description 1
235000006886 Zingiber officinale Nutrition 0.000 description 1
230000009471 action Effects 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
230000004075 alteration Effects 0.000 description 1
230000003466 anti-cipated effect Effects 0.000 description 1
125000003118 aryl group Chemical group 0.000 description 1
230000004888 barrier function Effects 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
229910002092 carbon dioxide Inorganic materials 0.000 description 1
239000001569 carbon dioxide Substances 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
KYKAJFCTULSVSH-UHFFFAOYSA-N chloro(fluoro)methane Chemical compound F[C]Cl KYKAJFCTULSVSH-UHFFFAOYSA-N 0.000 description 1
238000004140 cleaning Methods 0.000 description 1
235000016213 coffee Nutrition 0.000 description 1
235000013353 coffee beverage Nutrition 0.000 description 1
238000011109 contamination Methods 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
230000001627 detrimental effect Effects 0.000 description 1
238000004821 distillation Methods 0.000 description 1
230000009977 dual effect Effects 0.000 description 1
235000013399 edible fruits Nutrition 0.000 description 1
230000000694 effects Effects 0.000 description 1
238000005485 electric heating Methods 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
238000000855 fermentation Methods 0.000 description 1
230000004151 fermentation Effects 0.000 description 1
125000001153 fluoro group Chemical group F* 0.000 description 1
230000004907 flux Effects 0.000 description 1
238000005194 fractionation Methods 0.000 description 1
235000008397 ginger Nutrition 0.000 description 1
230000005484 gravity Effects 0.000 description 1
UKACHOXRXFQJFN-UHFFFAOYSA-N heptafluoropropane Chemical class FC(F)C(F)(F)C(F)(F)F UKACHOXRXFQJFN-UHFFFAOYSA-N 0.000 description 1
229910052739 hydrogen Inorganic materials 0.000 description 1
239000001257 hydrogen Substances 0.000 description 1
230000001771 impaired effect Effects 0.000 description 1
230000010354 integration Effects 0.000 description 1
239000013067 intermediate product Substances 0.000 description 1
238000012432 intermediate storage Methods 0.000 description 1
239000011872 intimate mixture Substances 0.000 description 1
239000007791 liquid phase Substances 0.000 description 1
230000008018 melting Effects 0.000 description 1
238000002844 melting Methods 0.000 description 1
235000015205 orange juice Nutrition 0.000 description 1
239000002245 particle Substances 0.000 description 1
239000000575 pesticide Substances 0.000 description 1
239000002243 precursor Substances 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
239000002002 slurry Substances 0.000 description 1
239000007787 solid Substances 0.000 description 1
238000000638 solvent extraction Methods 0.000 description 1
239000000126 substance Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
- C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Virology (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Gastroenterology & Hepatology (AREA)
Genetics & Genomics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Oncology (AREA)
Tropical Medicine & Parasitology (AREA)
Animal Behavior & Ethology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Communicable Diseases (AREA)
Pharmacology & Pharmacy (AREA)
AIDS & HIV (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicinal Preparation (AREA)
Extraction Or Liquid Replacement (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

ZA200301740A 2000-09-04 2001-09-03 HIV peptides from conserved regions in gas P17 and P24 and their application in e.g. vaccines. ZA200301740B (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
NO20004413A NO314588B1 (no)	2000-09-04	2000-09-04	HIV-peptider, antigener, vaksinesammensetning, immunoassay- testsett og en fremgangsmåte for å påvise antistoffer indusert av HIV

Publications (1)

Publication Number	Publication Date
ZA200301740B true ZA200301740B (en)	2004-06-21

Family

ID=19911533

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ZA200301740A ZA200301740B (en)	2000-09-04	2001-09-03	HIV peptides from conserved regions in gas P17 and P24 and their application in e.g. vaccines.

Country Status (19)

Country	Link
US (2)	US7009037B2 (no)
EP (2)	EP1878742A3 (no)
JP (2)	JP2004508381A (no)
CN (2)	CN1282656C (no)
AR (2)	AR033998A1 (no)
AT (1)	ATE406380T1 (no)
AU (3)	AU8270601A (no)
BR (1)	BR0114036A (no)
CA (1)	CA2421193A1 (no)
DE (1)	DE60135564D1 (no)
EA (1)	EA006308B1 (no)
ES (1)	ES2312465T3 (no)
HU (1)	HUP0303134A3 (no)
MY (1)	MY136081A (no)
NO (1)	NO314588B1 (no)
NZ (2)	NZ535148A (no)
SK (1)	SK287917B6 (no)
WO (1)	WO2002020554A2 (no)
ZA (1)	ZA200301740B (no)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2023031579A1 (en) *	2021-09-02	2023-03-09	113 Botanicals Limited	Extraction

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1307130A4 (en)	2000-02-04	2005-01-12	Beth Israel Hospital	VACCINE AGAINST THE VIRUS OF HUMAN IMMUNODEFICIENCY
EP2045282B1 (en) *	2005-08-26	2011-03-23	Novo Nordisk A/S	A method of modifying a macromolecular system
FI120376B (fi) *	2007-01-17	2009-09-30	Next Biomed Technologies Nbt O	Menetelmä biomuokatun, korkean affiniteetin polypeptidin valmistamiseksi
FI120349B (fi)	2007-03-07	2009-09-30	Next Biomed Technologies Nbt O	Menetelmä fuusiopolypeptidin valmistamiseksi
EP2344143A1 (en)	2008-09-09	2011-07-20	Mukesh Harilal Shukla	Bioactive composition for the treatment of the hiv/aids, method for manufacturing and using the same
WO2010045659A1 (en)	2008-10-17	2010-04-22	American Gene Technologies International Inc.	Safe lentiviral vectors for targeted delivery of multiple therapeutic molecules
US9733242B2 (en)	2012-10-07	2017-08-15	Sevident, Inc.	Devices for capturing analyte
US9910040B2 (en)	2012-07-09	2018-03-06	Sevident, Inc.	Molecular nets comprising capture agents and linking agents
FR2957933B1 (fr) *	2010-03-24	2012-04-27	Seppic Sa	Vaccin vivant pour maladies aviaires
EP2550362B1 (en)	2010-03-25	2017-01-04	Oregon Health&Science University	Cmv glycoproteins and recombinant vectors
US9493514B2 (en) *	2011-01-06	2016-11-15	Bionor Immuno As	Dimeric scaffold proteins comprising HIV-1 GP120 and GP41 epitopes
CA2832109C (en)	2011-06-10	2021-07-06	Oregon Health & Science University	Cmv glycoproteins and recombinant vectors
EP2568289A3 (en)	2011-09-12	2013-04-03	International AIDS Vaccine Initiative	Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies
US9402894B2 (en)	2011-10-27	2016-08-02	International Aids Vaccine Initiative	Viral particles derived from an enveloped virus
JP6310909B2 (ja) *	2012-06-06	2018-04-11	ビオノールイミュノエーエスＢｉｏｎｏｒＩｍｍｕｎｏＡｓ	免疫原及び投薬反応物として使用するためのウイルスタンパク質に由来するペプチド
EP2679596B1 (en)	2012-06-27	2017-04-12	International Aids Vaccine Initiative	HIV-1 env glycoprotein variant
CN105189465B (zh)	2013-03-21	2019-02-26	赛诺菲-安万特德国有限公司	合成含有乙内酰脲的肽产物
WO2014147129A1 (en)	2013-03-21	2014-09-25	Sanofi-Aventis Deutschland Gmbh	Synthesis of cyclic imide containing peptide products
EP2848937A1 (en)	2013-09-05	2015-03-18	International Aids Vaccine Initiative	Methods of identifying novel HIV-1 immunogens
US10058604B2 (en)	2013-10-07	2018-08-28	International Aids Vaccine Initiative	Soluble HIV-1 envelope glycoprotein trimers
EP3069730A3 (en)	2015-03-20	2017-03-15	International Aids Vaccine Initiative	Soluble hiv-1 envelope glycoprotein trimers
EP3072901A1 (en)	2015-03-23	2016-09-28	International Aids Vaccine Initiative	Soluble hiv-1 envelope glycoprotein trimers
JP6890831B2 (ja)	2015-07-08	2021-06-18	アメリカンジーンテクノロジーズインターナショナルインコーポレイテッド	Ｈｉｖ予備免疫化および免疫療法
US10137144B2 (en)	2016-01-15	2018-11-27	American Gene Technologies International Inc.	Methods and compositions for the activation of gamma-delta T-cells
DK3402483T3 (da)	2016-01-15	2024-01-02	American Gene Tech Int Inc	Fremgangsmåder og sammensætninger til aktivering af gamma-delta-T-celler
US10888613B2 (en)	2016-02-08	2021-01-12	American Gene Technologies International Inc.	Method of producing cells resistant to HIV infection
DK3426777T3 (da)	2016-03-09	2022-04-25	American Gene Tech Int Inc	Kombinationsvektorer og fremgangsmåder til behandling af cancer
US11976292B2 (en)	2016-06-08	2024-05-07	American Gene Technologies International Inc.	Non-integrating viral delivery system and methods related thereto
IL284348B2 (en)	2016-07-08	2025-06-01	American Gene Tech Int Inc	Hiv pre-immunization and immunotherapy
JP7176756B2 (ja)	2016-07-21	2022-11-22	アメリカンジーンテクノロジーズインターナショナルインコーポレイテッド	パーキンソン病を処置するためのウイルスベクター
CA3057142A1 (en)	2017-04-03	2018-10-11	American Gene Technologies International Inc.	Compositions and methods for treating phenylketonuria
CA3064442A1 (en)	2017-06-16	2018-12-20	American Gene Technologies International Inc.	Methods and compositions for the activation of tumor cytotoxicity via human gamma-delta t-cells
US11352646B2 (en)	2018-11-05	2022-06-07	American Gene Technologies International Inc.	Vector system for expressing regulatory RNA
RU2727673C1 (ru) *	2019-08-09	2020-07-22	Федеральное государственное унитарное предприятие «Государственный научно-исследовательский институт особо чистых биопрепаратов» Федерального медико-биологического агентства	Антитела против белка р17 ВИЧ-1 субтипа А

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NZ235538A (en) *	1989-10-12	1992-06-25	Viral Technologies Inc	Peptides immunoreactive with antibodies to hiv p17; carrier-bound peptides, vaccines, immunoassay and a method for forming antibody enriched sera
SE468168B (sv)	1990-02-20	1992-11-16	Replico Medical Ab	Hiv-1, p24 peptider, diagnostiska antigener och foerfarande foer saerskiljande diagnostik av preliminaert hiv-1 positiva serumprov
DE4039925A1 (de) *	1990-12-14	1992-06-17	Behringwerke Ag	Ausgewaehlte peptide des gruppenspezifischen antigens (gag) von humanem immundefizienzvirus (hiv), ihre herstellung und verwendung
SE9101863D0 (sv) *	1991-06-13	1991-06-13	Replico Medical Ab	Peptider, diagnostiskt antigen, vaccinkomposition och foerfarande foer selektering av hiv-stammar
US6525173B1 (en)	1997-01-02	2003-02-25	Universidade Federal De Minas Gerais	Process for expression and production of recombinant protein hybrid protein (p24/p17) derived from human immunodeficiency viruses (HIV-1)
GB9703802D0 (en) *	1997-02-24	1997-04-16	Kingsman Susan M	Anti-hiv peptides and proteins
US5972339A (en) *	1997-11-13	1999-10-26	The General Hospital Corporation	Method of eliciting anti-HIV-1 helper T cell responses
CA2685270C (en) *	1998-05-13	2014-07-29	Pharmexa Inc.	Expression vectors for stimulating an immune response and methods of using the same
NO311807B1 (no)	1999-03-04	2002-01-28	Bionor Immuno As	HIV-peptider, antigener, vaksinepreparater, immunoassay- testsett og en metode for påvisning av antistoffer fremkalt av HIV

2000
- 2000-09-04 NO NO20004413A patent/NO314588B1/no not_active IP Right Cessation
2001
- 2001-09-03 JP JP2002525174A patent/JP2004508381A/ja active Pending
- 2001-09-03 NZ NZ535148A patent/NZ535148A/en not_active IP Right Cessation
- 2001-09-03 EP EP07014954A patent/EP1878742A3/en not_active Withdrawn
- 2001-09-03 DE DE60135564T patent/DE60135564D1/de not_active Expired - Lifetime
- 2001-09-03 SK SK402-2003A patent/SK287917B6/sk not_active IP Right Cessation
- 2001-09-03 HU HU0303134A patent/HUP0303134A3/hu unknown
- 2001-09-03 CA CA002421193A patent/CA2421193A1/en not_active Abandoned
- 2001-09-03 BR BR0114036-1A patent/BR0114036A/pt not_active IP Right Cessation
- 2001-09-03 EP EP01961444A patent/EP1322665B1/en not_active Expired - Lifetime
- 2001-09-03 WO PCT/NO2001/000362 patent/WO2002020554A2/en not_active Ceased
- 2001-09-03 ZA ZA200301740A patent/ZA200301740B/en unknown
- 2001-09-03 NZ NZ524556A patent/NZ524556A/en not_active IP Right Cessation
- 2001-09-03 CN CNB018157424A patent/CN1282656C/zh not_active Expired - Fee Related
- 2001-09-03 ES ES01961444T patent/ES2312465T3/es not_active Expired - Lifetime
- 2001-09-03 AT AT01961444T patent/ATE406380T1/de not_active IP Right Cessation
- 2001-09-03 AU AU8270601A patent/AU8270601A/xx active Pending
- 2001-09-03 US US10/129,331 patent/US7009037B2/en not_active Expired - Fee Related
- 2001-09-03 AU AU2001282706A patent/AU2001282706B2/en not_active Ceased
- 2001-09-03 EA EA200300336A patent/EA006308B1/ru not_active IP Right Cessation
- 2001-09-03 CN CNA2006101517487A patent/CN101104636A/zh active Pending
- 2001-09-04 MY MYPI20014139A patent/MY136081A/en unknown
- 2001-09-04 AR ARP010104196A patent/AR033998A1/es active IP Right Grant
2005
- 2005-08-26 US US11/211,576 patent/US7612168B2/en not_active Expired - Fee Related
2007
- 2007-06-13 AU AU2007202739A patent/AU2007202739B2/en not_active Ceased
2008
- 2008-12-03 AR ARP080105262A patent/AR071262A2/es not_active Application Discontinuation
2011
- 2011-06-08 JP JP2011128389A patent/JP2011219481A/ja active Pending

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2023031579A1 (en) *	2021-09-02	2023-03-09	113 Botanicals Limited	Extraction
GB2610556A (en) *	2021-09-02	2023-03-15	113 Botanicals Ltd	Extraction

Also Published As

Publication number	Publication date
HUP0303134A2 (hu)	2005-03-29
EA200300336A1 (ru)	2003-08-28
CN1282656C (zh)	2006-11-01
CN1460111A (zh)	2003-12-03
AU2001282706B2 (en)	2007-03-22
AU2007202739A1 (en)	2007-07-05
JP2004508381A (ja)	2004-03-18
AR033998A1 (es)	2004-01-21
DE60135564D1 (de)	2008-10-09
MY136081A (en)	2008-08-29
US20070237783A1 (en)	2007-10-11
HK1059940A1 (en)	2004-07-23
US7009037B2 (en)	2006-03-07
AU2007202739B2 (en)	2009-12-03
EP1322665B1 (en)	2008-08-27
BR0114036A (pt)	2003-07-22
JP2011219481A (ja)	2011-11-04
EP1878742A2 (en)	2008-01-16
NZ524556A (en)	2005-01-28
NO314588B1 (no)	2003-04-14
US7612168B2 (en)	2009-11-03
EP1322665A2 (en)	2003-07-02
EA006308B1 (ru)	2005-10-27
EP1878742A3 (en)	2008-04-30
NO20004413D0 (no)	2000-09-04
WO2002020554A3 (en)	2002-06-13
AU8270601A (en)	2002-03-22
WO2002020554A2 (en)	2002-03-14
ATE406380T1 (de)	2008-09-15
US20040115615A1 (en)	2004-06-17
HUP0303134A3 (en)	2012-09-28
NO20004413L (no)	2002-03-05
NZ535148A (en)	2007-06-29
CA2421193A1 (en)	2002-03-14
CN101104636A (zh)	2008-01-16
AR071262A2 (es)	2010-06-09
ES2312465T3 (es)	2009-03-01
SK4022003A3 (en)	2003-09-11
SK287917B6 (sk)	2012-03-02

Publication	Publication Date	Title
ZA200301740B (en)	2004-06-21	HIV peptides from conserved regions in gas P17 and P24 and their application in e.g. vaccines.
US6589422B2 (en)	2003-07-08	Apparatus and method for extracting biomass
EP1210161B1 (en)	2003-12-10	Apparatus and method for extracting biomass
EP1216084A1 (en)	2002-06-26	Apparatus and method for separating mixed liquids
US20020195329A1 (en)	2002-12-26	Apparatus and methods for removing solvent residues
US6667015B1 (en)	2003-12-23	Apparatus and method for extracting biomass
AU766475C (en)	2004-09-09	Apparatus and method for removing solvent residues
EP1345665B1 (en)	2006-06-28	Apparatus and method for extracting biomass
EP1210157B1 (en)	2006-08-23	Apparatus and method for reducing residual solvent levels